Oryzon Genomics has entered into a binding heads of agreement to distribute HealthLinx's OvPlex in Spain.

The agreement also includes the extension of license rights to Andorra, France, Italy and Portugal.

Oryzon Genomics is focused to exploit biomarkers identified through genomics and proteomics in
diagnostics, personalised medicine and therapy fields.

HealthLinx managing director Nick Gatsios said Oryzon’s knowledge of the biomarker space and early stage cancer diagnostic tests made us distribution partners.

"Such knowledge means that the product will be marketed clearly and effectively to the right clinicians and gynecological oncologists, which should mean the women in Spain who are most at risk are aware, and can use OvPlex," Gatsios said.